Still, you largely own biotech stocks for the promise of their research and development (R&D) pipeline and the company's ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A ...

Researchers have uncovered numerous genetic variants that seem to play a role in people’s responses to painkillers and other ...

ANIP may be acquired soon with a potential offer exceeding $8 billion and contingent on FDA approval of a new drug filed in ...

The pharmaceutical industry faces stringent regulatory requirements to ensure the safety, efficacy, and quality of drug products. Among these, Current Good Manufacturing Practice (CGMP) guidelines set ...

Investors with a lot of money to spend have taken a bearish stance on Regeneron Pharmaceuticals REGN. And retail traders should know. We noticed this today when the trades showed up on publicly ...

The UK PM Society’s Market Access Interest Group (MAIG) undertook a comprehensive survey on the topic of market access, where it sought the views of both industry and agency. The answers were ...

15 analysts have expressed a variety of opinions on Vertex Pharmaceuticals (NASDAQ:VRTX) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A ...

During the last three months, 4 analysts shared their evaluations of Rhythm Pharmaceuticals (NASDAQ:RYTM), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot ...

Priti Mohile discusses pharmaceutical marketing in India and how little has changed of late. She investigates what needs to change and the challenges and opportunities presented in this area.

Based on the one-year price targets offered by 7 analysts, the average target price for Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is $10.14, with a high estimate of $14 and a low estimate of $6.